James Dahlman is an Assistant Professor in the Georgia Tech BME Department. He studied RNA design and gene editing as a post-doc with Feng Zhang at the Broad Institute, and received his PhD from MIT and Harvard Medical School in 2014, where he studied RNA delivery with Robert Langer and Daniel Anderson.
The Lab for Precision Therapies at Georgia Tech, also called the 'Dahlman Lab', works at the interface of drug delivery, nanotechnology, genomics, and gene editing. James has designed nanoparticles that deliver RNAs to the lung and heart; these nanoparticles have been used by over ten labs across the US to date. He has also developed targeted in vivo combination therapies; nanoparticles deliver multiple therapeutic RNAs at once, in order to manipulate several nodes on a single disease pathway. More recently, he developed a method to quantify the targeting, biodistribution, and pharmacokinetics of dozens to hundreds of distinct nanoparticles at once directly in vivo.
Finally, James uses molecular biology to rationally design the genetic drugs he delivers. He recently reported 'dead' guide RNAs; these engineered RNAs can be used to simultaneously up- and down-regulate different genes in a single cell using Cas9.
James has won the NSF, NDSEG, NIH OxCam, Whitaker Graduate, and LSRF Fellowships, the Weintraub Graduate Thesis Award, and was recently named a Bayer Young Investigator and Parkinson's Disease Foundation Young Investigator. He has had significant help along the way. Besides having great scientific advisors, James has been lucky to mentor excellent students, including two that were finalists for the Rhodes Scholarship.
In the Dahlman Lab, we focus on the interface between nanotechology, molecular biology, and genomics. We design drug delivery vehicles that target RNA and other nucleic acids to cells in the body. We have delivered RNAs to endothelial cells, and have treated heart disease, cancer, inflammation, pulmonary hypertension, emphysema, and even vein graft disease. Because we can deliver RNAs to blood vessels at low doses, sometimes we decide to deliver multiple therapeutic RNAs to the same cell at once. These 'multigene therapies' have been used to treat heart disease and cancer. Why is this important? Most diseases are caused by combinations of genes, not a single gene. We also rationally design the nucleic acids we want to deliver. For example, we re-engineered the Cas9 sgRNA to turn on genes, instead of turning them off. This enabled us to easily turn on gene A and turn off gene B in the same cell.
We focus on developing and applying label-free linear and nonlinear optical methods, along with advanced signal processing methods, to gain access to novel forms of functional and molecular contrast for a variety of biomedical applications.
Peng Qiu received his B.S. degree from the University of Science and Technology of China, and a Ph.D. degree from the University of Maryland College Park, both in electrical engineering. After spending three years as a postdoctoral fellow in the Center for Cancer Systems Biology at Stanford, and three years as an assistant professor in the Department of Bioinformatics and Computational Biology at UT MD Anderson Cancer Center, he joined the Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University.
Bioinformatics and computational biology, machine learning, data integration, progression analysis, single-cell analysis, flow cytometry
His main research interests are in the area of bioinformatics and computational biology, focusing on machine learning, visualization, signal processing, systems modeling and network analysis.